We report on three cases of meningococcal disease caused by ciprofloxacin-resistant Neisseria meningitidis, one in North Dakota and two in Minnesota. The cases were caused by the same serogroup B strain. To assess local carriage of resistant N. meningitidis, we conducted a pharyngeal-carriage survey and isolated the resistant strain from one asymptomatic carrier. Sequencing of the gene encoding subunit A of DNA gyrase (gyrA) revealed a mutation associated with fluoroquinolone resistance and suggests that the resistance was acquired by means of horizontal gene transfer with the commensal N. lactamica. In susceptibility testing of invasive N. meningitidis isolates from the Active Bacterial Core surveillance system between January 2007 and January 2008, an additional ciprofloxacin-resistant isolate was found, in this case from California. Ciprofloxacin-resistant N. meningitidis has emerged in North America.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMoa0806414 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection of and (and Its Resistance to Ciprofloxacin): Validation of a Molecular Biology Tool for Rapid Diagnosis and Treatment.
Antibiotics (Basel)
October 2024
Institute for Health Research Aragon, 50009 Zaragoza, Spain.
Article Synopsis
- Infections caused by pathogens like gonorrhea can present similar clinical symptoms, leading to common treatments that may increase antibiotic resistance.
- Certest Biotec created two diagnostic kits for the simultaneous detection of gonorrhea and fluoroquinolone resistance, showing promising performance in a clinical study.
- The study analyzed 540 clinical samples, revealing high sensitivity and specificity of the kits compared to traditional diagnostic methods, enhancing diagnosis and treatment while addressing rising antibiotic resistance.
Meningococcal disease, caused by the bacterium Neisseria meningitidis, is a rare but life-threatening illness that requires prompt antibiotic treatment for patients and antibiotic prophylaxis for their close contacts. Historically, N. meningitidis isolates in the United States have been largely susceptible to the antibiotics recommended for prophylaxis, including ciprofloxacin.
View Article and Find Full Text PDFEmergence of ciprofloxacin- and penicillin-resistant isolates in Japan between 2003 and 2020 and its genetic features.
Antimicrob Agents Chemother
November 2023
Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Article Synopsis
- A study analyzed 290 meningococcal isolates from Japan between 2003 and 2020 to assess their susceptibility to eight antibiotics, including penicillin and ciprofloxacin.
- Most isolates were found susceptible to chloramphenicol, ceftriaxone, meropenem, minocycline, and rifampicin, while two isolates were resistant to azithromycin and some were resistant or intermediate to penicillin and ciprofloxacin.
- Genetic analysis revealed that around 40% of penicillin-resistant isolates belonged to unique Japanese strains, indicating that resistance traits appear to be spread clonally rather than through gene transfer from other bacteria.
Antimicrobial Resistance and Molecular Typing of Neisseria gonorrhoeae Isolates From the Eastern Cape Province in South Africa.
Sex Transm Dis
December 2023
Global Antibiotic Research & Development Partnership (GARDP), Geneva, Switzerland.
Background: There is a paucity of Neisseria gonorrhoeae antimicrobial resistance data from resource-constrained settings because of the lack of diagnostic testing and limited scale of surveillance programs. This study aimed to determine the antimicrobial resistance profile of N. gonorrhoeae in the rural Eastern Cape province of South Africa.
View Article and Find Full Text PDFAustralian Gonococcal Surveillance Programme Annual Report, 2022.
Commun Dis Intell (2018)
August 2023
Neisseria Reference Laboratory and World Health Organization Collaborating Centre for STI and AMR, Sydney. NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW, 2031, Australia.
The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae for more than 40 years. In 2022, a total of 8,199 isolates from patients in the public and private sectors, in all jurisdictions, were tested for in vitro antimicrobial susceptibility by standardised methods. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!